TW202202145A - Medicine of organogermanium for wound healing and method of using the same - Google Patents

Abstract

A medicine for wound healing, which promotes wound healing by inducing interferon production of a body. Forms of the medicine include powders, ointments, emulsions, liquids, etc., which can promote rapid healing of various skin wounds and ulcers in the body. There is no obvious exudate from the wound during the healing process. The tissue surface recovers and is smooth after the healing process, and almost no scar is left. The invention also discloses a method of using the above-mentioned medicine.

Description

Organic germanium medicine for promoting wound healing and using method thereof

The invention relates to a medicine for promoting wound healing, which can be used for the healing of surgical incisions, wounds, lacerations, abrasion injuries, cuts, burns, scalds, bedsores and ulcers.

There are many reasons for wounds. In addition to skin wounds such as wounds, lacerations, abrasion injuries, knife wounds, burns, scalds, diabetic ulcers and bedsores caused by long-term bed rest, ulcers in the body are also common wounds.

Wound healing is a complex and slow process. New epithelial tissue and connective tissue are formed by the migration and proliferation of wound cells during treatment, thus promoting cell migration, differentiation and proliferation, etc., which are helpful for wound healing. . Previous studies have shown that so-called "epidermal growth factors" including epidermal growth factor (EGF), transforming growth factor-α (TGF-α), and heparin-binding epidermal growth factor (HB-EGF), etc. "EGF family", considered to be the key to regulating keratinocyte proliferation at the wound edge (Paul Martin, "Wound Healing-Aiming for Perfect Skin Regeneration", p75-81, SCIENCE, Vol.276, 4 April, 1997) , will be released in large quantities at the site of epidermal damage.

In addition, studies have also found that exogenous epidermal growth factor and transforming growth factor-α applied to the burn site of pig back can enhance the regeneration of epidermal cells (GL Brown et al., J. Exp. Med. 163, 1319 (1986); GS Schultz et al., Science 235, 350 (1987)). When these growth factors act on the epidermis, they act as motogens and mitogens to drive wound closure (Y. Barrandon and H. Green, Cell 50, 1131 (1987)).

Previous in vitro model studies on the recovery of intestinal epithelial cells by various cytokines and peptide growth factors (Diagnass, AU, Podolsky, DK, Gastroenterology, 1993, 105(5):1323 -1332) results showed that four factors, including transforming growth factor-α, epidermal growth factor, interleukin-1β (interleukin-1β, IL-1β) and interferon-γ (interferon-γ, IFN-γ), promoted the Production of bioactive TGF-β1 peptide on wounded IEC-6 intestinal monolayer cell membranes enhanced intestinal epithelial wound healing by 2.3- to 5.5-fold.

In the prior art, some agents for promoting wound healing are mainly composed of growth factors, but exogenous growth factors have the following disadvantages in the treatment of wounds: (1) Growth factors are unstable proteins that are easily decomposed during storage , when administered orally, it will be digested and destroyed before entering the blood; (2) the growth factor is absorbed slowly by the human body, and will be rapidly decomposed, therefore, the use effect of externally applied ointment is also limited; (3) ) Many growth factors are species specific and, if administered parenterally, are recognized as foreign and rejected, triggering a dangerous immune response. For the above reasons, exogenous growth factors are not ideal wound healing drugs. The literature also states that there is no evidence that parenterally administered growth factors reach the skin, connective and supportive tissues.

The invention provides a medicine for promoting wound healing, which can induce the production of interferon-γ (IFN-γ) in vivo, promote the production of TGF-β1 peptide in vivo, and then accelerate wound healing.

The present invention also provides a method for effectively exerting the effect of promoting wound healing by using the aforementioned medicament.

The medicine for promoting wound healing provided by the present invention is mainly composed of an organic germanium compound which can stimulate the production of interferon in the body.

Because the present invention adopts organic germanium compound, and the organic germanium compound has antibacterial, anti-inflammatory, analgesic and other effects, so when applied to wound healing treatment, it can simultaneously produce the effects of disinfection, anti-inflammatory and analgesic. The present invention can also solve the difficulties encountered by exogenous growth factors in healing wounds. And it has been confirmed that the medicine for promoting wound healing of the present invention has the following benefits compared with the previous medicines: (1) it can inhibit the production of exudate, the wound is easy to keep clean, and the burden of medical care and the pain of patients is greatly reduced; (2) it is suitable for Healing treatment of open or large wounds, and the healing is rapid; (3) It leaves almost no scars, suitable for the healing of medical cosmetic surgery wounds; (4) It is suitable for the promotion of skin wound healing caused by diabetes or long-term bed rest.

In order to make the above-mentioned and other objects, features and advantages of the present invention more obvious and easy to understand, the following specific embodiments are given and described in detail in conjunction with the accompanying drawings.

The drugs with the above-mentioned wound healing pharmacology disclosed in the present invention include but are not limited to the following types of organic germanium compounds: (1) bis-carboxyalkyl germanium sesquioxide and its derivatives, (2) Germane compounds (germanes), (three) azatricyclic germanium compounds (germatranes), (four) spirogermanium compounds, (five) germanium porphyrines and (six) germanocene compounds (germanocenes). (1) to (4) are further explained as follows.

上式中之R1、R2、R3為H、取代或未取代的低碳烷基(alkyl)如甲基(methyl)或乙基(ethyl)等、芳基(aryl)、雜芳基(hetaryl)、取代或未取代的胺基(amino group)或醯胺基(amido group)等；X為羥基(OH)、O-Na、O-K、鹼性胺基(basic amino group)、芳基(aryl)或雜芳基(hetaryl)等。(1) bis-carboxyalkyl germanium sesquioxide and its derivatives: The chemical representation of such organic germanium compounds is as follows:

R1, R2, R3 in the above formula are H, substituted or unsubstituted lower alkyl (alkyl) such as methyl (methyl) or ethyl (ethyl), etc., aryl (aryl), heteroaryl (hetaryl) , substituted or unsubstituted amino group (amino group) or amide group (amido group), etc.; X is hydroxyl (OH), O-Na, OK, basic amino group (basic amino group), aryl (aryl) Or heteroaryl (hetaryl) and the like.

Among such organic germanium compounds, the most representative and most widely studied and applied is bis-carboxyethyl germanium sesquioxide (Ge-132), which has high water solubility and immunological activity.

式中之R1、R2、R3為H、取代或未取代的低碳烷基(alkyl)如甲基(methyl)或乙基(ethyl)等；R4為烷基；X為取代或未取代的醣苷基(glycosyl group)。(2) Germane compounds (germanes): The representative molecular formula is as follows:

R1, R2, R3 in the formula are H, substituted or unsubstituted lower alkyl (alkyl) such as methyl (methyl) or ethyl (ethyl), etc.; R4 is alkyl; X is substituted or unsubstituted glycoside base (glycosyl group).

The most representative of such compounds is 6-O-3-trimethylgermane-propyl-β-D-glucopyranoside (6-O-[3-(trimethyl-germyl)propyl) codenamed GeOH. ]-β-D-glucopyranoside), studies have shown that its water solubility and immune activity are higher than Ge-132.

式中之R為苯基(benzyl group)或苯溴基(bromobenzyl group)、肉桂酸基([-CH(C₆ H₄ OH)CH₂ COOH])、咖啡酸基([-CH(C₆ H₃ (OH)₂ )CH₂ COOH])等，這些雜氮三環鍺化合物也皆已被證明具有低毒性和良好的免疫活性。(3) Aza-azatricyclic germanium compounds (germatranes): immunologically active aza-azatricyclic germanium compounds, the representative formula of its molecular structure includes but is not limited to the following formula:

R in the formula is phenyl group (benzyl group) or phenyl bromide group (bromobenzyl group), cinnamic acid group ([-CH(C ₆ H ₄ OH)CH ₂ COOH]), caffeic acid group ([-CH(C ₆ ) H ₃ (OH) ₂ )CH ₂ COOH]), etc., these aza-tricyclic germanium compounds have also been proved to have low toxicity and good immune activity.

(4) Spirogermanium compound: Immunostimulatory helical germanium compounds, including but not limited to 3-(2, 8, 9-trioxa-aza-1-germatricyclo[3.3.3.0] undecane-1-yl)-caffeic Acid, 4, 4-dialkyl-4-germacyclohexanon or 8,8-dialkyl-8-germaazaspiro(4,5)decan etc.

The above-mentioned various organogermanium compounds ((1)-(6)) have been attracting much attention for their anti-tumor, immunomodulatory, and interferon-inducing properties. Among them, bis-carboxyethylgermanium sesquioxide and its derivatives have long been found to have analgesic action, anti-inflammatory action, antioxidant effect and antihypoxia effect ( antihyproxic effect) (VG Lakhtin, NG Komalenkova, VG Bykovchenko, GN Yakovleva, EA Chernyshev, Synthesis and application of organogermanium compounds, Polymer Science Series D, Volume 4, Issue 3, pp 221-227, 2011-07-01), Immunology Immunomodulating action, antiviral action (LG Menchikov1 and MA Ignatenko, Biological Activity of Organogermanium Compounds (A Review), Pharmaceutical Chemistry Journal, Vol. 46, No. 11, February, 2013; DW Niesel , CB Hess, YJ Cho, KD Klimpel and GR Klimpel, Infection and Immunity, June 1986, p. 828-833 Vol. 52, No. 3).

Studies have shown that after giving mice an oral dose of 300 mg/kg of Ge-132, significant levels of interferon activity were detected in mouse serum at 20 hours, and the interferon activity reached a maximum of 320 U/ml at 24 hours (Hisashi ASO; Fujio SUZUKI; Takahiro YAMAGUCHI; Yoshiro HAYASHI; Takusaburo EBINA and Nakao ISHIDA, Microbiol. Immunol. Vol. 29(1), 65-74, 1985). Ge-132 is not substantially toxic (Asai K., Miracle Cure: Organic Germanium. New York: Japan Publications/ Kodansha International via Harper and Row, 1980; Stephen A. Levine, Journal of Orthomolecular Medicine, (1987) Vol. 2 No. . 2, 83-87; Takashi Nakamura, Taizo Nagura, Katsuyuki Sato and Masao Ohnishi, Biosci. Microbiota Food Health, 31(2): 37–45 (2012)), high water solubility relative to other organogermanium compounds , is the most representative and widely studied and used organogermanium compound, except that it has been used as an anti-inflammatory agent, analgesic (Japanese Patent Publication Sho 62-93293), and heat injury therapeutic agent (Japanese Patent Publication 2002-193802) , immune stimulants, etc., are also used as health supplements, widely added in health care products and cosmetics. Nonetheless, it has never before been used as a primary agent for promoting wound healing.

In addition to Ge-132, other germanium trioxide derivatives (germanium sesquioxides) have also been studied, and some have been shown to have better ability to induce interferon-γ than Ge-132 (Sumi Choi, Changwon Oh, Jeongsoo Han, Jina Park, Jee Hye Choj, Na Young Min, Kwang-Ho Lee, Ae Ja Park, Yeo Jin Kim, Su Jeong Jan, Synthesis and biological evaluation of water-soluble organogermanium, European Journal of Medicinal Chemistry 45 (2010) 1654 –1656). Other organic compounds, such as germana tricyclic germanium compounds (germatranes), spiro germanium compounds, porphyrin germanium compounds, germanocene compounds, etc., have all been proved to have immune and antitumor activities, and These pharmacological activities are derived from their properties that induce the production of interferon-gamma (F. Suzuki, RR Brutkiewicz and RB Pollard, Br. J. Cancer (1985), 52, 757-763; N. Kakimoto, K. Miyao, M. . Akiba, in "Frontiers of Organogermanium, -Tin, Lead Chemistry", E. Lukevics, L. Ignatovich eds., Latvian Institute of Organic Synthesis, 1993; Marcel Gielen Edward RT Tiekink, Metallotherapeutic Drugs And Metal-Based Diagnostic Agents: The Use Of Metals In Medicine, John Wiley & Sons Ltd., 2005).

Although the above-mentioned organogermanium compounds have the properties of inducing interferon-γ and stimulating the production of transforming growth factor-β1 in the body, they have not been used as the main agent for wound healing so far. Or the transforming growth factor produced by in vivo injection cannot easily reach the superficial mucosa of the wound, especially in the case of low-dose administration for general medical purposes.

The drug use method of the present invention solves the above-mentioned problems, so that the promoting effect of the drug on wound healing can be fully exhibited. Stimulates the production of interferon-γ in the tissue, and also causes the production of transforming growth factor-β1 in the wound surface layer, so that the effect of promoting wound healing can be exerted; (2) The application of high concentrations or even pure drugs to produce sufficient transformation Growth factor-β1, so that the effect of wound healing can be manifested; (3) Improve drug absorption, such as choosing liquid drugs or solid drugs with higher water solubility and keeping the wound properly moist to promote the dissolution of drugs, so as to facilitate the tissue Absorption.

The above medicine using method of the present invention enables the excellent effect of organogermanium compound to promote wound healing to be revealed. Because organogermanium compounds have been shown to be extremely low-toxic, there is no risk of causing excessive drug doses in the body. Furthermore, since the drug dose is subject to the rate of absorption of the drug, it can be limited by adjusting the dissolution of the drug (solid drug) and the total amount of drug administered. Especially for topical application at the wound site, the risk of excessive drug doses can be completely ruled out. In addition to the organic germanium compound alone, the medicament of the present invention can also further include other adjuvants and additives; the form of the medicament can be powder, ointment, emulsion or liquid. When using ointment, emulsion or liquid, you can apply it directly; when using powder, you can scatter the medicine quantitatively on the wound, and then spray water mist on the wound to moisten the medicine, so as to spread the medicine evenly, and help the medicine dissolve for tissue absorption. .

After taking the above medicine and method of use, carry out the experiment of skin wound healing (detailed in the embodiment), observe the following effects of the present invention: (1) the healing rate of the wound is very fast, obviously faster than applying commercially available wound healing ointment (2) In the absence of antiseptics, the wound did not become inflamed during the healing process; (3) The exudate of the wound was greatly reduced, and the application of high concentrations of the drug could effectively inhibit the production of exudate; (4) There was no contamination. The scab phenomenon, the smooth appearance of the skin after the wound has healed.

In addition to promoting the healing of external wounds by external application, the use of the medicament of the present invention does not exclude the use of oral or injection methods for promoting the healing of ulcers and wounds in vivo under limited doses. The present invention further provides an internal or external medicament with the medicament as the main component and in the form of powder, ointment, emulsion or liquid.

Examples: The following examples of the present invention are intended to demonstrate the effects of the present invention, and cannot be used as a limitation on the scope of the patent application of the present invention.

(1) Test drug The wound healing test was performed with bis-carboxyethylgermanium sesquioxide (Ge-132), which was a pure Ge-132 fine powder purchased from the market, and was first sieved with a 100-mesh sieve before use. For comparison, the experiment was carried out with the following three combinations, and normal saline was used as the wound cleaning agent, wherein agent A was pure Ge-132 powder without other additives; agent B was mixed powder containing 5 wt% Ge-132 132, the remaining 95 wt% are pharmaceutical grade ZnO (purity > 99.9%); agent C is a commercially available silver amine cream, each gram of cream contains 10 mg of silver sulfadiazine (silver sulfadazine); agent D is medical vaseline , as the control group.

(2) Experimental animals The test animals were two New Zealand white rabbits born at 95 days, weighing 2.35 kg and 2.42 kg respectively. The rabbits were anesthetized by injection of Acetylpromazine (3 mg/kg) before the experiment, and then infiltrated with Octocaine®50. Then remove the hair in the middle area of the rabbit's back. After completion, use a rectangular soldering iron of 1 cm x 1.5 cm preheated to 500°C. Select two spots on each side of the spine in the hair removal area, and touch them for three seconds respectively, causing four A burning wound.

(3) Test method The burnt epidermis of the rabbit was washed with physiological saline, then wiped with a medical cotton ball, and then the test agent was applied. Wherein agent A and agent B are powders, first weigh the powder to be used (the weight is calculated by using 0.01 g of powder per cm ² wound), then disperse the powder in the wound area, and then spray water mist to the wound with a spray bottle to make The powder is moderately moistened, and finally the moistened powder is spread evenly with a glass applicator; Agent C is ointment, applied to the wound according to the manufacturer's instructions; Agent D is Vaseline, smeared to cover the wound as a control group. Apply once a day during the application period. Before applying the medicine, first wash the wound with physiological saline, wipe it with a medical cotton ball, and then take a picture to measure the size of the wound and observe the change. The size of the wound is measured using the area measurement function of the PHOTOSHOP software after taking a photo.

(4) Test results The test results include: 1) changes in wound appearance; 2) changes and comparisons in wound size.

1) Observation of changes in wound appearance In this experiment, two rabbits were used to carry out two sets of repeated experiments. The skin of the rabbit's burn area was charred brown, and the results showed that there was little difference in appearance between the two groups of experiments. The two sets of results are described as follows:

The first set of test results: Wounds treated with agent A: There was no obvious change in the appearance of the scorched epidermis at the initial stage; on the 14th day, the scorched epidermis was completely detached at one time, leaving only the middle area of the wound, which was 9.56% of the original wound, and the surface of the new epidermis of the healed part It was smooth (see Figure 2A), without inflammation and scabbing; the wound was completely healed on the 20th day of application (see Figure 3A). There is no inflammation in the process of wound healing, only a very slight and almost negligible scar appears in the middle part of the final healing, and the fur gradually grows; Wounds treated with agent B: On the 14th day (that is, the point when the scorched epidermis was completely detached when treated with agent A), the surrounding part of the scorched epidermis was detached. The area has not healed yet (see Figure 2B); on the 20th day (that is, when the wound was completely healed when agent A was treated), the area of the wound was reduced to 6.12% (see Figure 3B); on the 25th day, the wound was fully healed. There is no inflammation in the process of wound healing, but there is mild scabbing, and the smoothness of the epidermis after the wound is healed is worse than that of the agent A; The wound treated with agent C: On the 14th day (that is, the point when the scorched epidermis was completely detached during the treatment with agent A), the surrounding part of the scorched epidermis was detached, and the wound area expanded to 132.83% of the original wound (please refer to Figure 2C) ; On the 20th day (that is, when the wound was completely healed when the agent A was treated), the scorched epidermis was completely detached, and the unhealed wound was 98.45% of the original wound area (please refer to Figure 3C); on the 43rd day, the wound was completely heal. There is obvious inflammation in the process of wound healing. During the application, the wound area once expanded, and the phenomenon of scabbing is far more obvious than that of the B agent. Control wound treated with agent D: on the 14th day (that is, the point when the scorched epidermis was completely detached during agent A treatment), the scorched epidermis in the surrounding part of the wound was partially detached. % of the area has not healed (please refer to Figure 2D); on the 18th day, the scorched epidermis was completely detached; on the 20th day (that is, when the wound was completely healed when the agent A was treated), the wound was reduced to 7.62% of the original area ( See Figure 3D); on day 36, the wound was completely healed. In the process of wound healing, there is slight inflammation, and the scab phenomenon is more obvious than that of the B agent.

The test results of the second group The test results of the second group showed that although the days for the burnt epidermis to be completely detached and the days for the wound to heal completely were little different from those of the first group, the inflammation, scab and the smoothness of the healed epidermis of each agent were significantly different. and so on, the order of pros and cons is the same as that of the first group. The results of the two groups of experiments are shown in Table 1. Table 1: Observation of changes in wound appearance group Observation of wound characteristics administer the drug Agent A Agent B Agent C Agent D First group Number of days until the burnt epidermis is completely detached 14 18 20 18 Days to complete wound healing 20 25 43 36 Inflammation ◎ ○ X △ scab ◎ ○ X △ Epidermal smoothness after healing ◎ ○ X △ Second Group Number of days until the burnt epidermis is completely detached 13 17 twenty two 18 Days to complete wound healing 19 twenty three 48 38 Inflammation ◎ ○ X △ scab ◎ ○ X △ Epidermal smoothness after healing ◎ ○ X △ Note: ◎excellent; ○good; △fair; X poor.

2) Changes in wound size The comparison of wound size is based on the time point when the burnt epidermis is completely detached and the wound is completely healed when the agent A is treated as the sampling day, and the size of the sampled wound is compared with the original wound, expressed as a percentage (%), the result As shown in Table 2. Table 2: Comparison of changes in wound size group Application days The ratio of control to original wound size (%) Agent A Agent B Agent C Agent D First group 0 100 100 100 100 14 9.56 38.62 132.83 68.54 20 0 6.12 98.45 7.62 Second Group 0 100 100 100 100 13 8.92 39.03 146.60 71.37 19 0 6.56 115.75 9.03

The test results in Table 2 show that the scorched epidermis completely detached from the scorched epidermis on the 14th day in the first group administered agent A, and the wound area was reduced to 9.56% of the original wound area (please refer to Figure 2A), and other agents were administered at this time The ratio of each wound control to the original wound is: agent B is 38.62% of the original wound area (please refer to Figure 2B), agent C is 132.83% (please refer to Figure 2C), agent D (control group) is 68.54% (please refer to Figure 2C) See Figure 2D). The experimental results of the second group showed a similar healing situation to the first group. The burnt epidermis was completely detached in the A group on the 13th day, and the wound was completely healed on the 19th day. At the same time point, the B, C and D agents The area ratio of the unhealed wound to the original wound is also recorded in Table 2, which is close to the changes in the first group.

The above experimental results show that when the drug containing the organogermanium compound of bis-carboxyethylgermanium sesquioxide is administered, either agent A or agent B has a significant promoting effect on wound healing, and also inhibits inflammation, mild scabbing, and During the healing process, the wound has almost no exudate (exudate) and is kept clean, and the surface is smooth and scar-free after healing. The effect of agent A is significantly better than that of agent B, showing that the higher the drug concentration, the better the effect of promoting wound healing. good. This experiment also confirms that using organic germanium compound as a single drug can simultaneously exert the effects of wound disinfection, anti-inflammatory, sterilization and inhibition of exudate production, but understandably, this does not mean that other drugs or additives such as antibiotics and analgesics need to be excluded. , anesthetics, vitamins, etc.

The present invention also provides a method for promoting wound healing and/or treating wounds, comprising using the aforementioned medicament. The methods of use include external application, oral administration, injection, etc. to administer the aforementioned drugs to patients. The drug can also be used for external application in the form of powder or its water slurry, ointment, emulsion, etc., and oral or injection in the form of solution, powder suspension, etc., but it is not limited to this.

Although the present invention has been disclosed as above with examples, it is not intended to limit the present invention. Those with ordinary knowledge in the technical field to which the present invention pertains can make some changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention should be determined by the scope of the appended patent application.

without

Figure 1: Wound condition on day 7 after application. Figure 2: Wound condition on day 14 after application. Figure 3: Wound condition on day 20 after application.

Claims (18)

A medicine for promoting wound healing, which comprises an organic germanium compound which can stimulate the production of interferon in the body as the main component. The medicine for promoting wound healing according to claim 1, wherein the organic germanium compound is selected from at least one of the following: bis-carboxyalkyl germanium sesquioxide, bis-carboxyalkyl germanium sesquioxide, bis-carboxyalkyl germanium sesquioxide Derivatives of semi-oxides, germanes, germana tricyclic germanium compounds (germatranes), spirogermanium compounds, germanium porphyrines and germanocenes. The medicine for promoting wound healing as claimed in claim 2, wherein the molecular formula of the bis-carboxyalkyl germanium sesquioxide is:

R1, R2, R3 in the formula are the following reactive groups: H, substituted or unsubstituted lower alkyl (alkyl) such as methyl (methyl) or ethyl (ethyl), aryl (aryl), heteroaryl ( hetaryl), substituted or unsubstituted amino group (amino group) or one of amido group (amido group); X is hydroxyl (OH), O-Na, OK, basic amino group (basic amino group), aryl group (aryl) or one of heteroaryl (hetaryl). The medicine for promoting wound healing according to claim 2, wherein the bis-carboxyalkylgermanium sesquioxide is bis-carboxyethylgermanium sesquioxide (Ge-132). The medicine for promoting wound healing as claimed in claim 2, wherein the molecular formula of the germane compound is:

R1, R2 and R3 in the formula are one of H, substituted or unsubstituted lower alkyl such as methyl or ethyl; R4 is alkyl; X is substituted or unsubstituted One of the glycosyl groups. The medicine for promoting wound healing according to claim 5, wherein the germane compound is 6-O-3-trimethylgermane-propyl-β-D-glucopyranoside (6-O-[3- (tri-methylgermyI)propyl]-β-D-glucopyranoside (GeOH)). The medicine for promoting wound healing according to claim 2, wherein the molecular formula of the aza-tricyclic germanium compound (germatranes) is:

R in the formula is phenyl group (benzyl group), phenyl bromide group (bromobenzyl group), cinnamic acid group [-CH(C ₆ H ₄ OH)CH ₂ COOH], caffeic acid group [-CH(C ₆ H ₃ ( One of OH) ₂ )CH ₂ COOH]. The medicine for promoting wound healing according to claim 2, wherein the spiro germanium compound is 3-(2,8,9-trioxa-aza-1-germatricyclo-[3,3,3,0]-undecane-1 -yl)caffeic Acid, 4,4-dialkyl-4-germa-cyclohexano or 8,8-dialkyl-8-germaazaspiro(4,5)decan. The medicine for promoting wound healing according to claim 2, wherein the germanocene compound is decaphenylgermanocenes. The medicine for promoting wound healing according to claim 2, wherein the germanium porphyrines is dialkyl-5,10,15,20-tetra-[30,50bis(tertiary butyl)benzene base] porphyrin germanium (dialkyl-5,10,15,20-tetra-[30,50-bis-(t-butyl)phenyl]-porphynatogermanium). The medicine for promoting wound healing according to claim 1, which is in one of the following forms: solution, powder suspension, emulsion, ointment and powder. The medicine for promoting wound healing according to claim 1, wherein the concentration of the organic germanium compound is 0.3 wt% or more. The medicine for promoting wound healing according to claim 12, wherein the concentration of the organic germanium compound is 1 wt% or more. The medicine for promoting wound healing according to claim 13, wherein the concentration of the organic germanium compound is 2 wt% or more. The medicine for promoting wound healing as described in claim 1 further includes at least one of the following additives: sterilant, antibiotic, wetting agent, vitamin, supplement and other skin wound healing agent. The medicine for promoting wound healing as claimed in claim 1, which is used in at least one of the following ways: external application, oral administration and injection. A use of the medicament for promoting wound healing according to any one of claims 1 to 16 in preparing a medicament for treating wounds, wherein the administration mode of the medicament for treating wounds is selected from external application, oral administration and injection. When the medicine for promoting wound healing according to any one of claims 1 to 15, when it is administered as powder, the powder is directly applied to the wound, and water mist is sprayed at appropriate time to keep the wound moderately moist.

Images